Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Blavatnik Family Foundation to Provide $10 Million Grant for Immunobiology Research at Yale

Published: Tuesday, April 09, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Grant supports work of immunobiologists Ruslan Medzhitov and Richard Flavell.

Scientists at Yale University will test a new theory of inflammation and chronic disease, thanks to a $10 million grant from the Blavatnik Family Foundation, the charitable organization headed by American industrialist and philanthropist Len Blavatnik.

The grant supports the work of immunobiologists Ruslan Medzhitov and Richard Flavell, who have posed a unifying theory to describe how inflammation can impact the body’s homeostatic control mechanisms to trigger the onset of disease.

Yale President-elect Peter Salovey expressed the University’s gratitude to the Blavatnik Family Foundation for what he called “an extremely generous and far-sighted” contribution.

“The research now underway in the Medzhitov and Flavell laboratories has the potential to transform our understanding of human biology and our approaches to the most intractable diseases. This grant will accelerate their work at Yale’s Department of Immunobiology, which is world-renowned for leading major advances in innate and adaptive immunity,” Salovey said.

“The Blavatnik Family Foundation is committed to the advancement of breakthrough scientific discoveries,” said Blavatnik, founder and chairman of Access Industries.

Blavatnik continued, “This new theory represents a paradigm shift in the science of chronic diseases and may lead to new prevention strategies, treatments, and even cures for many disorders.”

Much of Yale’s prominence in the area is already attributed to Medzhitov and Flavell, who have led pioneering studies on the control of inflammation by the innate immune system.

Flavell chairs Yale’s Department of Immunobiology, which he helped to found 24 years ago. He is the Sterling Professor of Immunobiology and a Howard Hughes Medical Institute investigator.

Ruslan Medzhitov, the David W. Wallace Professor of Immunobiology, is also a Howard Hughes Medical Institute investigator. He is widely recognized, along with the late Charles A. Janeway Jr., for his part in elucidating the role of the innate immune system, for which he received a Blavatnik Award for Young Scientists in 2007.

In February, Medzhitov and Flavell were jointly awarded the 2013 Vilcek Prize for Biomedical Science. Now, they are building on their discoveries in immunology to seek the molecular origins of disease.

The healthy human body regulates its own tissues and organs to maintain key physiological variables in a beneficial balance, a “steady state” that scientists call homeostasis.

The body even gets some outside help from microbes, or commensal microorganisms, that reside in locations such as the digestive tract and play a part in maintaining core body temperature, blood pressure, blood sugar, sleep patterns, and a host of metabolic processes needed for fitness and survival.

When infection or tissue damage occurs, the body’s innate immune system activates inflammatory mechanisms that help to combat these dangers and restore a proper balance, at least in the short term.

Medzhitov and Flavell postulate that these same inflammatory mechanisms can have a damaging effect on homeostatic controls-an effect they see as a root cause of many serious health disorders. They plan a detailed study to define the molecular links between inflammation, commensal microorganisms, and chronic disease.

Dr. Robert Alpern, dean of Yale School of Medicine, said: “The Blavatnik Family Foundation's generous grant will support game-changing research in the field of immunobiology. This work offers a whole new way to look at the causes of many chronic illnesses, including cardiovascular disease, type 2 diabetes, autoimmune diseases, asthma and allergies, neurodegenerative diseases such as Alzheimer’s disease, and cancer. A few years from now, I am optimistic that, as a result of this important research, we will be in a position to develop new therapeutics that can broadly impact human health and quality of life.”

Blavatnik is deeply committed to supporting innovation in biomedical research and higher education. The Blavatnik Family Foundation is an active supporter of leading educational, scientific, cultural, and charitable institutions throughout the world.

In 2007, the Blavatnik Family Foundation established the Blavatnik Awards for Young Scientists, awarded through the New York Academy of Sciences, to recognize innovative and impactful accomplishments in the life sciences, physical sciences, mathematics, and engineering.

The Blavatnik Family Foundation has also supported the Broad Institute at Harvard and MIT and provided seed funding at Harvard for highly promising, early-stage research in the life sciences.

In 2010, The Blavatnik Family Foundation made a gift to establish the Blavatnik School of Government at the University of Oxford, to train outstanding graduates from across the world in the skills and responsibilities of government.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
Wednesday, July 08, 2015
Researchers Solve Multiple Sclerosis Puzzle
Yale study shows the role that T cells play in MS.
Monday, May 18, 2015
New Tool To Explore Mysteries Of The Immune System
Yale scientists use CyTOF to study a range of conditions.
Monday, April 20, 2015
Cold Virus Replicates Better At Cooler Temperatures
Study shows that the immune response to rhinovirus is influenced by temperature.
Tuesday, January 06, 2015
New Class of Synthetic Molecules Mimics Antibodies
A Yale University lab has crafted the first synthetic molecules that have both the targeting and response functions of antibodies.
Wednesday, December 24, 2014
Protein Predicts Response To New Immunotherapy Drug
Trial shows that response to treatment may be predicted by the presence of an immune-suppressing protein in non-cancerous immune cells.
Friday, November 28, 2014
Immune System Surprise Hints at New Strategy for Fighting HIV
Surprising twist may open a new avenue in the fight.
Tuesday, November 18, 2014
Immune Cells get Cancer-Fighting Boost From Nanomaterials
Yale researchers used bundled carbon nanotubes to incubate cytotoxic T cells.
Monday, August 18, 2014
Commonly Used Drugs May Not Be Effective Against Autoimmune Illness
The study appears in the Cell Press journal Immunity.
Tuesday, March 18, 2014
Yale Team Implants Human Innate Immune Cells in Mice
Groundbreaking study has reproduced human immune function at a level not seen previously.
Tuesday, March 18, 2014
Lung Disease and Melanoma: a Common Molecular Mechanism?
Researchers have solved a biological mystery about the common genesis of many serious diseases such as asthma and metastatic melanoma.
Monday, September 02, 2013
Drug Preserves Beta Cells in New Cases of Type 1 Diabetes
A drug in clinical trials has been shown to preserve insulin-producing pancreatic beta cells in nearly half of subjects newly diagnosed with type 1 diabetes.
Tuesday, August 06, 2013
Nature’s Own Nanoparticles Harnessed to Target Disease
Using a novel form of immune-genetic therapy, researchers have successfully inhibited a strong immune allergic inflammatory response in the skin of mice.
Friday, July 12, 2013
Promising Drug Prevents Cancer Cells from Shutting Down Immune System
An investigational drug that targets the immune system’s ability to fight cancer is showing promising results in Yale Cancer Center (YCC) patients.
Monday, June 10, 2013
Combined Immunotherapy Shows Promising Results Against Advanced Melanoma
Combining two cancer immunotherapy drugs in patients with advanced melanoma produced rates of tumor regression that appeared greater than in prior trials with either drug alone.
Monday, June 10, 2013
Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos